+ Watch AVNR
on My Watchlist
A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.
Nuedexta revenues have been increasing steadily, but not enough to justify a rebound from 2.16 to 3.16 and a market cap of 432M despite an ongoing double digit quarterly burn and only 70M in the bank as of the end of Q3. I suspect traders are looking for positive news on Nuedexta from the CHMP, but European approval is a notorious false start for companies with products that are already approved in the US. Other pipeline compounds remain in early clinical development.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions